ProQR Therapeutics Newsroom

Institutions Own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares but Retail Investors Control 46% of the Company

Yahoo FinanceJun 23 10:31 ET

ProQR Announces Presentation on Its Axiomer RNA Editing Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it

GlobeNewswireJun 18 08:00 ET

Shareholders in ProQR Therapeutics (NASDAQ:PRQR) Are in the Red If They Invested Five Years Ago

Yahoo FinanceMay 13 07:12 ET

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

Earnings Call TranscriptsMay 11 17:57 ET

ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital

ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital

Dow JonesMay 10 10:24 ET

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMay 10 10:24 ET

Express News | HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

BenzingaMay 10 08:21 ET

ProQR Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 145.1% HC Wainwright & Co. → $5 Reiterates Buy → Buy 04/18/2024 -1.96% Citigroup $1.8 → $2 Main

BenzingaMay 10 08:20 ET

Express News | ProQR Therapeutics' Cash And Cash Equivalents And Short Term Financial Assets Of €102.7M As Of End Of Q1 Provides Runway Into Mid-2026

BenzingaMay 9 07:58 ET

Express News | ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate

BenzingaMay 9 07:56 ET

Express News | ProQR Therapeutics NV - EUR 102.7 Mln as of End of Q1 Providing Runway Into Mid-2026

ReutersMay 9 07:10 ET

ProQR Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 9 07:07 ET · Announcements

Express News | ProQR Announces First Quarter 2024 Operating and Financial Results

ReutersMay 9 07:00 ET

Express News | ProQR Therapeutics Q1 Net Income EUR -7.658 Million Vs. Ibes Estimate EUR -9.67 Million

ReutersMay 9 07:00 ET

Express News | ProQR Therapeutics Q1 EPS EUR -0.09 Vs. Ibes Estimate EUR -0.11

ReutersMay 9 07:00 ET

Express News | ProQR Therapeutics Q1 Basic EPS EUR -0.09

ReutersMay 9 07:00 ET

Express News | ProQR Therapeutics Q1 Revenue EUR 4.45 Million Vs. Ibes Estimate EUR 3.14 Million

ReutersMay 9 07:00 ET

Express News | ProQR Therapeutics Q1 Operating Income EUR -8.075 Million

ReutersMay 9 07:00 ET

ProQR Therapeutics' RNA Program Shows Promise

TipRanksMay 8 08:59 ET

ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer RNA Editing

BenzingaMay 8 08:27 ET